Brief: Cosmo Pharmaceuticals FY Operating Income EUR -3.236 Million
09/03/2026 06:01
Mar 09 (Reuters) - Cosmo Pharmaceuticals FY EBITDA EUR 9.52 million. FY operating expenses EUR -53.792 million FY EPS EUR -0.226 FY gross profit EUR 50.556 million outlook FY revenue EUR 7-8 million vs. IBES estimate EUR 140.2 million
Recent news on Cosmo NV
See all newsFocus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Ireland's Cosmo recurring revenue rises on winlevi growth, reaffirms FY guidance
Brief: Cosmo Pharmaceuticals H1 EPS EUR -0.279
Cosmo Pharma's male hair loss treatment shows sustained hair growth in year‑long study
Europe Research Roundup: Airbus ,Bechtle, Salzgitter